StoxAcutaas Chemicals vs Rubicon Research: share price & financials comparison
NSE: ACUTAAS vs RUBICON · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Acutaas Chemicals vs Rubicon Research at a glance
Acutaas Chemicals (ACUTAAS) has a market capitalisation of ₹31,001 Cr, against ₹27,466 Cr for Rubicon Research (RUBICON). Over the past year Rubicon Research has returned +176.3%, compared with +124.2% for Acutaas Chemicals. On valuation, Acutaas Chemicals trades at a lower P/E of 70.6 versus 84.6. Acutaas Chemicals earns a higher return on equity (23.6% vs 22.9%). Acutaas Chemicals comes out ahead on size, valuation, profitability, growth, financial health and momentum. Rubicon Research comes out ahead on technicals. Across the scored metrics below, Acutaas Chemicals leads on 12 and Rubicon Research on 2. On StoxGud's 10-point checklist, Acutaas Chemicals scores 9/10 and Rubicon Research scores 8/10.
| Metric | Acutaas Chemicals | Rubicon Research |
|---|---|---|
| Size | ||
| Market cap | ₹31,001 Cr | ₹27,466 Cr |
| Revenue (latest FY) | ₹1,339 Cr | ₹1,754 Cr |
| Net profit (latest FY) | ₹356 Cr | ₹247 Cr |
| Valuation | ||
| P/E | 70.6 | 84.6 |
| P/B | 16.69 | 19.39 |
| Dividend yield | 0.04% | 0.00% |
| Profitability | ||
| Return on equity | 23.6% | 22.9% |
| Net profit margin | 27.6% | 15.5% |
| Operating margin | 39.1% | 23.8% |
| Growth | ||
| Revenue growth (YoY) | +42.7% | +39.9% |
| Net profit growth (YoY) | +73.3% | +68.0% |
| Revenue CAGR (multi-year) | +26.7% | — |
| Financial health | ||
| Debt to equity | 0.00 | 0.28 |
| Momentum | ||
| 1-month return | +19.3% | +5.3% |
| 1-year return | +124.2% | +176.3% |
| 3-year CAGR | +87.5% | — |
| 5-year CAGR | +48.9% | — |
| Distance from 52W high | -5.4% | -10.8% |
| Technicals | ||
| RSI (14) | 68 | 65 |
| Price vs 200-day avg | +31.9% | +35.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Acutaas Chemicals | Rubicon Research |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 9/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Acutaas Chemicals or Rubicon Research?
Acutaas Chemicals has a market cap of ₹31,001 Cr and Rubicon Research has a market cap of ₹27,466 Cr as of 06 Nov 2026.
Which has a lower P/E, Acutaas Chemicals or Rubicon Research?
Acutaas Chemicals has the lower P/E: Acutaas Chemicals trades at 70.6 and Rubicon Research at 84.6.
Which gave better returns in the last year, Acutaas Chemicals or Rubicon Research?
Rubicon Research did better: Acutaas Chemicals returned +124.2% and Rubicon Research returned +176.3% over one year.
Is Acutaas Chemicals or Rubicon Research a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Acutaas Chemicals scores 9/10 and Rubicon Research scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.